Pharmacokinetic and pharmacodynamic implications in inhalable antimicrobial therapy

Advanced Drug Delivery Reviews

Volumn 85, Issue , 2015, Pages 57-64

  Mukker, Jatinder Kaur ^a   Singh, Ravi Shankar Prasad ^a   Derendorf, Hartmut ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Antimicrobials; Inhalation therapy; Minimum inhibitory concentration; Pharmacodynamics; Pharmacokinetics; Sputum concentrations; Systemic exposure; Time kill curve

Indexed keywords

CONTROLLED DRUG DELIVERY; DRUG INTERACTIONS; PHARMACODYNAMICS; RESPIRATORY THERAPY; TARGETED DRUG DELIVERY;

ANTIMICROBIALS; INHALATION THERAPY; MINIMUM INHIBITORY CONCENTRATION; SYSTEMIC EXPOSURE; TIME-KILL CURVE;

PHARMACOKINETICS;

ANTIINFECTIVE AGENT; CIPROFLOXACIN; COLISTIMETHATE; GENTAMICIN; LEVOFLOXACIN; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SPUTUM LEVEL; HUMAN; LUNG INFECTION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; REVIEW; BIOLOGICAL MODEL; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG; MODELS, BIOLOGICAL;

EID: 84930089002     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.03.002     Document Type: Review

References (108)

1. Heijerman H., Westerman E., Conway S., Touw D., Doring G. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J. Cyst. Fibros. 2009, 8:295-315.
2. Karvouniaris M., Makris D., Triantaris A., Zakynthinos E. Inhaled antibiotics for nosocomial pneumonia. Inflamm. Allergy Drug Targets 2012, 11:116-123.
3. Muttil P., Wang C., Hickey A.J. Inhaled drug delivery for tuberculosis therapy. Pharm. Res. 2009, 26:2401-2416.
4. Rubin B.K., Williams R.W. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. Respiration 2014, 88:177-184.
5. Traini D., Young P.M. Delivery of antibiotics to the respiratory tract: an update. Expert Opin. Drug Deliv. 2009, 6:897-905.
6. Patton J.S., Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 2007, 6:67-74.
7. Bosworth D.G., Nielson D.W. Effectiveness of home versus hospital care in the routine treatment of cystic fibrosis. Pediatr. Pulmonol. 1997, 24:42-47.
8. Hoppentocht M., Hagedoorn P., Frijlink H.W., de Boer A.H. Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: a critical evaluation. Eur. J. Pharm. Biopharm. 2014, 86:23-30.
9. Fiel S.B. Aerosolized antibiotics in cystic fibrosis: an update. Expert Rev. Respir. Med. 2014, 8:305-314.
10. Hoiby N. Antibiotic therapy for chronic infection of pseudomonas in the lung. Annu. Rev. Med. 1993, 44:1-10.
11. Coutinho H.D., Falcao-Silva V.S., Goncalves G.F. Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers. Int. Arch. Med. 2008, 1:24.
12. Hickey A.J., Misra A., Fourie P.B. Dry powder antibiotic aerosol product development: inhaled therapy for tuberculosis. J. Pharm. Sci. 2013, 102:3900-3907.
13. Doring G., Conway S.P., Heijerman H.G., Hodson M.E., Hoiby N., Smyth A., Touw D.J. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Respir. J. 2000, 16:749-767.
14. Peters S. Cystic fibrosis: a review of pathophysiology and current treatment recommendations. S. D. Med. 2014, 67:148-151.
15. Kaur J., Muttil P., Verma R.K., Kumar K., Yadav A.B., Sharma R., Misra A. A hand-held apparatus for "nose-only" exposure of mice to inhalable microparticles as a dry powder inhalation targeting lung and airway macrophages. Eur. J. Pharm. Sci. 2008, 34:56-65.
16. Muttil P., Kaur J., Kumar K., Yadav A.B., Sharma R., Misra A. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur. J. Pharm. Sci. 2007, 32:140-150.
17. Pandey R., Khuller G.K. Antitubercular inhaled therapy: opportunities, progress and challenges. J. Antimicrob. Chemother. 2005, 55:430-435.
18. Wang C., Hickey A.J. Isoxyl aerosols for tuberculosis treatment: preparation and characterization of particles. AAPS PharmSciTech 2010, 11:538-549.
19. Dharmadhikari A.S., Kabadi M., Gerety B., Hickey A.J., Fourie P.B., Nardell E. Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis. Antimicrob. Agents Chemother. 2013, 57:2613-2619.
20. Sacks L.V., Pendle S., Orlovic D., Andre M., Popara M., Moore G., Thonell L., Hurwitz S. Adjunctive salvage therapy with inhaled aminoglycosides for patients with persistent smear-positive pulmonary tuberculosis. Clin. Infect. Dis. 2001, 32:44-49.
21. H.R., Turner M.T., McGowan K., Nardell E E., Sabbag R. Inhaled kanamycin in the treatment of multidrug-resistant tuberculosis: a study of five patients. Infect. Dis. Clin. Pract. 1998, 7:49-53.
22. Meibohm B., Derendorf H. Pharmacokinetic/pharmacodynamic studies in drug product development. J. Pharm. Sci. 2002, 91:18-31.
23. Schmidt S., Barbour A., Sahre M., Rand K.H., Derendorf H. PK/PD: new insights for antibacterial and antiviral applications. Curr. Opin. Pharmacol. 2008, 8:549-556.
24. Bilton P.R.D., Cooper P., Gallagher C., Kolbe J., Charlton B. Phase III study of inhaled dry powder mannitol (Bronchitol™) in cystic fibrosis-results from the 6month open label phase, in: A102 advances in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2010, 181:A2338.
25. Geller D.E., Flume P.A., Griffith D.C., Morgan E., White D., Loutit J.S., Dudley M.N. Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob. Agents Chemother. 2011, 55:2636-2640.
26. Geller D.E., Flume P.A., Staab D., Fischer R., Loutit J.S., Conrad D.J. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am. J. Respir. Crit. Care Med. 2011, 183:1510-1516.
27. Goldfarb J., Wormser G.P., Inchiosa M.A., Guideri G., Diaz M., Gandhi R., Goltzman C., Mascia A.V. Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. J. Clin. Pharmacol. 1986, 26:222-226.
28. d'Angelo I., Conte C., La Rotonda M.I., Miro A., Quaglia F., Ungaro F. Improving the efficacy of inhaled drugs in cystic fibrosis: challenges and emerging drug delivery strategies. Adv. Drug Deliv. Rev. 2014, 75:92-111.
29. Touw D.J., Jacobs F.A., Brimicombe R.W., Heijerman H.G., Bakker W., Briemer D.D. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob. Agents Chemother. 1997, 41:184-187.
30. Cooney G.F., Lum B.L., Tomaselli M., Fiel S.B. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J. Clin. Pharmacol. 1994, 34:255-259.
31. Smith A.L., Ramsey B.W., Hedges D.L., Hack B., Williams-Warren J., Weber A., Gore E.J., Redding G.J. Safety of aerosol tobramycin administration for 3months to patients with cystic fibrosis. Pediatr. Pulmonol. 1989, 7:265-271.
32. Al-Amoud A.I., Clark B.J., Assi K.A., Chrystyn H. Determination of the bioavailability of gentamicin to the lungs following inhalation from two jet nebulizers. Br. J. Clin. Pharmacol. 2005, 59:542-545.
33. Yapa S.W.S., Li J., Patel K., Wilson J.W., Dooley M.J., George J., Clark D., Poole S., Williams E., Porter C.J., Nation R.L., McIntosh M.P. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob. Agents Chemother. 2014, 58:2570-2579.
34. Stass H., Delesen H., Nagelschmitz J., Staab D. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study. J. Aerosol Med. Pulm. Drug Deliv. 2014, 27:1-10.
35. Stass H., Delesen H., Nagelschmitz J., Willmann S., Edginton A. Ciprofloxacin PulmoSphere inhalational powder: a healthy volunteer study. American Thoracic Society International Conference, Toronto, Canada, Toronto, Canada 2008, G-50.
36. Geller D.E., Weers J., Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology. J. Aerosol Med. Pulm. Drug Deliv. 2011, 24:175-182.
37. Griese M., Eismann C., Borner G., Denk O., Schierholz J.M., Keller M., Mazurek H., Kappler M. A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI. J. Aerosol Med. Pulm. Drug Deliv. 2014, 27:185-192.
38. Hubert D., Leroy S., Nove-Josserand R., Murris-Espin M., Mely L., Dominique S., Delaisi B., Kho P., Kovarik J.M. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. J. Cyst. Fibros. 2009, 8:332-337.
39. Davis R.L., Koup J.R., Williams-Warren J., Weber A., Heggen L., Stempel D., Smith A.L. Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrob. Agents Chemother. 1987, 31:915-919.
40. Geller D.E., Pitlick W.H., Nardella P.A., Tracewell W.G., Ramsey B.W. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002, 122:219-226.
41. Cipolla D., Chan H.K. Inhaled antibiotics to treat lung infection. Pharm. Pat. Anal. 2013, 2:647-663.
42. European committee on antimicrobial susceptibility testing Breakpoint tables for interpretation of MICs and zone diameters, Version 2 2012, EUCAST, Sweden.
43. Ratjen F., Rietschel E., Kasel D., Schwiertz R., Starke K., Beier H., van Koningsbruggen S., Grasemann H. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J. Antimicrob. Chemother. 2006, 57:306-311.
44. Dalhoff A. Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients. Clin. Microbiol. Rev. 2014, 27:753-782.
45. Morosini M.I., Garcia-Castillo M., Loza E., Perez-Vazquez M., Baquero F., Canton R. Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips. J. Clin. Microbiol. 2005, 43:4480-4485.
46. Le J., Ashley E.D., Neuhauser M.M., Brown J., Gentry C., Klepser M.E., Marr A.M., Schiller D., Schwiesow J.N., Tice S., VandenBussche H.L., Wood G.C. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2010, 30:562-584.
47. Littlewood K.J., Higashi K., Jansen J.P., Capkun-Niggli G., Balp M.M., Doering G., Tiddens H.A., Angyalosi G. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis. J. Cyst. Fibros. 2012, 11:419-426.
48. Eisenberg J., Pepe M., Williams-Warren J., Vasiliev M., Montgomery A.B., Smith A.L., Ramsey B.W. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized tobramycin study group. Chest 1997, 111:955-962.
49. Lenoir G., Antypkin Y.G., Miano A., Moretti P., Zanda M., Varoli G., Monici Preti P.A., Aryayev N.L. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Paediatr. Drugs 2007, 9(Suppl. 1):11-20.
50. Barth A., Singh R., May R., Johnson J., Isaza R., Blumberg H.M., Vashakidze S., Peloquin C., Derendorf H., Kempker R. Levofloxacin dose optimization for multidrug resistant tuberculosis based on lung microdialysis in patients. ACCP annual meeting Atlanta, GA 2014.
51. Hutschala D., Kinstner C., Skhirtladze K., Mayer-Helm B.X., Zeitlinger M., Wisser W., Muller M., Tschernko E. The impact of perioperative atelectasis on antibiotic penetration into lung tissue: an in vivo microdialysis study. Intensive Care Med. 2008, 34:1827-1834.
52. Zeitlinger M., Muller M., Joukhadar C. Lung microdialysis-a powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract (mini-review). AAPS J. 2005, 7:E600-E608.
53. Zeitlinger M.A., Traunmuller F., Abrahim A., Muller M.R., Erdogan Z., Muller M., Joukhadar C. A pilot study testing whether concentrations of levofloxacin in interstitial space fluid of soft tissues may serve as a surrogate for predicting its pharmacokinetics in lung. Int. J. Antimicrob. Agents 2007, 29:44-50.
54. O'Riordan T., Faris M. Inhaled antimicrobial therapy. Respir. Care Clin. N. Am. 1999, 5:617-631.
55. O'Riordan T.G. Inhaled antimicrobial therapy: from cystic fibrosis to the flu. Respir. Care 2000, 45:836-845.
56. Bayer Ciproxin broad spectrum antibiotic. Product monograph 1987, Bayer Germany AG, Leverkusen, Germany.
57. Bergstrom C.A., Norinder U., Luthman K., Artursson P. Experimental and computational screening models for prediction of aqueous drug solubility. Pharm. Res. 2002, 19:182-188.
58. O.N.M. Budavari, P.E. Heckelman, J.F. Kinneary, The Merck index, 12th ed. ed., Merck & Co, Inc., Whitehouse Station, New Jersey, 1996.
59. 2 on the activity of antimicrobial agents in vitro. Eur. J. Clin. Microbiol. Infect. Dis. 1993, 12:519-526.
60. Dalhoff A., Schubert S., Ullmann U. Effect of pH on the in vitro activity of and propensity for emergence of resistance to fluoroquinolones, macrolides, and a ketolide. Infection 2005, 33(Suppl. 2):36-43.
61. Swift D., Asgharian B., Kimbell J.S. Use of mathematical aerosol deposition models in predicting the distribution of inhaled therapeutic aerosols. Inhalation Aerosol 2007, 502. Informa Healthcare USA, Inc., New York. second edition.
62. Labiris N.R., Dolovich M.B. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 2003, 56:588-599.
63. Chan H.K., Eberl S., Daviskas E., Constable C., Young I. Changes in lung deposition of aerosols due to hygroscopic growth: a fast SPECT study. J. Aerosol Med. 2002, 15:307-311.
64. Kuhn R.J. Pharmaceutical considerations in aerosol drug delivery. Pharmacotherapy 2002, 22:80S-85S.
65. Coates A.L., Allen P.D., MacNeish C.F., Ho S.L., Lands L.C. Effect of size and disease on estimated deposition of drugs administered using jet nebulization in children with cystic fibrosis. Chest 2001, 119:1123-1130.
66. Diot P., Palmer L.B., Smaldone A., DeCelie-Germana J., Grimson R., Smaldone G.C. RhDNase I aerosol deposition and related factors in cystic fibrosis. Am. J. Respir. Crit. Care Med. 1997, 156:1662-1668.
67. Mukhopadhyay S., Staddon G.E., Eastman C., Palmer M., Davies E.R., Carswell F. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Respir. Med. 1994, 88:203-211.
68. Zeman K.L., Wu J., Bennett W.D. Targeting aerosolized drugs to the conducting airways using very large particles and extremely slow inhalations. J. Aerosol Med. Pulm. Drug Deliv. 2010, 23:363-369.
69. Knudson R.J., Lebowitz M.D., Holberg C.J., Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am. Rev. Respir. Dis. 1983, 127:725-734.
70. Anderson P.J., Blanchard J.D., Brain J.D., Feldman H.A., McNamara J.J., Heyder J. Effect of cystic fibrosis on inhaled aerosol boluses. Am. Rev. Respir. Dis. 1989, 140:1317-1324.
71. Cazzola M., Blasi F., Terzano C., Matera M.G., Marsico S.A. Delivering antibacterials to the lungs: considerations for optimizing outcomes. Am. J. Respir. Med. 2002, 1:261-272.
72. Fauroux B., Itti E., Pigeot J., Isabey D., Meignan M., Ferry G., Lofaso F., Willemot J.M., Clement A., Harf A. Optimization of aerosol deposition by pressure support in children with cystic fibrosis: an experimental and clinical study. Am. J. Respir. Crit. Care Med. 2000, 162:2265-2271.
73. Ilowite J.S., Gorvoy J.D., Smaldone G.C. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am. Rev. Respir. Dis. 1987, 136:1445-1449.
74. Perry J.D., Laine L., Hughes S., Nicholson A., Galloway A., Gould F.K. Recovery of antimicrobial-resistant Pseudomonas aeruginosa from sputa of cystic fibrosis patients by culture on selective media. J. Antimicrob. Chemother. 2008, 61:1057-1061.
75. Foweraker J.E., Laughton C.R., Brown D.F., Bilton D. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J. Antimicrob. Chemother. 2005, 55:921-927.
76. Kirby A.E., Garner K., Levin B.R. The relative contributions of physical structure and cell density to the antibiotic susceptibility of bacteria in biofilms. Antimicrob. Agents Chemother. 2012, 56:2967-2975.
77. Pezzulo A.A., Tang X.X., Hoegger M.J., Alaiwa M.H., Ramachandran S., Moninger T.O., Karp P.H., Wohlford-Lenane C.L., Haagsman H.P., van Eijk M., Banfi B., Horswill A.R., Stoltz D.A., McCray P.B., Welsh M.J., Zabner J. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 2012, 487:109-113.
78. Gudmundsson A., Erlendsdottir H., Gottfredsson M., Gudmundsson S. Impact of pH and cationic supplementation on in vitro postantibiotic effect. Antimicrob. Agents Chemother. 1991, 35:2617-2624.
79. Squibb Bristol-Myers Azactam (aztreonam) injection, powder, for solution. Product Information 2007, Bristol-Myers Squibb Co, New York.
80. Dalhoff A. Immunomodulatory activities of fluoroquinolones. Infection 2005, 33(Suppl. 2):55-70.
81. Dalhoff A., Stubbings W., Schubert S. Comparative in vitro activities of the novel antibacterial finafloxacin against selected Gram-positive and Gram-negative bacteria tested in Mueller-Hinton broth and synthetic urine. Antimicrob. Agents Chemother. 2011, 55:1814-1818.
82. Bjarnsholt T., Ciofu O., Molin S., Givskov M., Hoiby N. Applying insights from biofilm biology to drug development-can a new approach be developed?. Nat. Rev. Drug Discov. 2013, 12:791-808.
83. Noble C.G., Barnard F.M., Maxwell A. Quinolone-DNA interaction: sequence-dependent binding to single-stranded DNA reflects the interaction within the gyrase-DNA complex. Antimicrob. Agents Chemother. 2003, 47:854-862.
84. Shen L.L., Baranowski J., Pernet A.G. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: specificity and cooperativity of drug binding to DNA. Biochemistry 1989, 28:3879-3885.
85. Shen L.L., Mitscher L.A., Sharma P.N., O'Donnell T.J., Chu D.W., Cooper C.S., Rosen T., Pernet A.G. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug-DNA binding model. Biochemistry 1989, 28:3886-3894.
86. Andes D., Craig W.A. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob. Agents Chemother. 2002, 46:1665-1670.
87. Craig W.A. Choosing an antibiotic on the basis of pharmacodynamics. Ear Nose Throat J. 1998, 77:7-11.
88. Ambrose P.G., Bhavnani S.M., Rubino C.M., Louie A., Gumbo T., Forrest A., Drusano G.L. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 2007, 44:79-86.
89. Dalla Costa T., Nolting A., Rand K., Derendorf H. Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. Int. J. Clin. Pharmacol. Ther. 1997, 35:426-433.
90. Mueller M., de la Pena A., Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob. Agents Chemother. 2004, 48:369-377.
91. Drusano G.L. Fluoroquinolone pharmacodynamics: prospective determination of relationships between exposure and outcome. J. Chemother. 2000, 12(Suppl. 4):21-26.
92. Mouton J.W., Punt N. Use of the t>MIC to choose between different dosing regimens of beta-lactam antibiotics. J. Antimicrob. Chemother. 2001, 47:500-501.
93. Barbour A., Scaglione F., Derendorf H. Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices. Int. J. Antimicrob. Agents 2010, 35:431-438.
94. Schmidt S., Gonzalez D., Derendorf H. Significance of protein binding in pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 2010, 99:1107-1122.
95. Hoffman A., Stepensky D. Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy. Crit. Rev. Ther. Drug Carrier Syst. 1999, 16:571-639.
96. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility test for bacterai that grow aerobically, Approved standard-ninth edition 2012, 32:M07-A9. CLSI, Wayne, Pa.
97. Liu P., Rand K.H., Obermann B., Derendorf H. Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. Int. J. Antimicrob. Agents 2005, 25:120-129.
98. Vaddady P.K., Lee R.E., Meibohm B. In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB. Future Med. Chem. 2010, 2:1355-1369.
99. Doring G., Hoiby N., Consensus Study G. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J. Cyst. Fibros. 2004, 3:67-91.
100. Levy S.B., Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 2004, 10:S122-S129.
101. Dalhoff A., Ambrose P.G., Mouton J.W. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection 2009, 37:296-305.
102. Jones H., Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst. Pharmacol. 2013, 2:e63.
103. Suri R., Metcalfe C., Wallis C., Bush A. Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respir. Med. 2007, 101:254-260.
104. Equi A., Balfour-Lynn I.M., Bush A., Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002, 360:978-984.
105. Redlich C.A., Tarlo S.M., Hankinson J.L., Townsend M.C., Eschenbacher W.L., Von Essen S.G., Sigsgaard T., Weissman D.N. S. American Thoracic Society Committee on Spirometry in the Occupational, Official American Thoracic Society technical standards: spirometry in the occupational setting. Am. J. Respir. Crit. Care Med. 2014, 189:983-993.
106. Orenstein D.M., Pattishall E.N., Nixon P.A., Ross E.A., Kaplan R.M. Quality of well-being before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis. Chest 1990, 98:1081-1084.
107. Nixon P.A., Orenstein D.M., Kelsey S.F., Doershuk C.F. The prognostic value of exercise testing in patients with cystic fibrosis. N. Engl. J. Med. 1992, 327:1785-1788.
108. Weber B., Hochhaus G. A pharmacokinetic simulation tool for inhaled corticosteroids. AAPS J. 2013, 15:159-171.